Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 12
Submit an article Journal homepage
5,749
Views
11
CrossRef citations to date
0
Altmetric
Original Articles

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

David Strausa Memorial Sloan Kettering Cancer Center, New York City, NY, USACorrespondence[email protected]
View further author information
,
Graham Collinsb Oxford Cancer and Hematology Center, Churchill Hospital, Oxford, UKView further author information
,
Jan Walewskic Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warsaw, PolandView further author information
,
Pier Luigi Zinzanid Institute of Hematology Seragnoli, University of Bologna, Bologna, ItalyView further author information
,
Andrew Grigge Department of Clinical Haematology, Austin Hospital, Melbourne, AustraliaView further author information
,
Anna Suredaf Institut Català d'Oncologia-Hospitalet, Hospital Quirón Dexeus, Barcelona, SpainView further author information
,
Arpad Illesg University of Debrecen, Faculty of Medicine, Debrecen, HungaryView further author information
,
Tae Min Kimh Seoul National University Hospital, Seoul, Republic of KoreaView further author information
,
Sergey Alekseevi Petrov Research Institute of Oncology, St. Petersburg, RussiaView further author information
,
Lena Spechtj Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Valeria Buccherik Hematology Service, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, BrazilView further author information
,
Anas Younesa Memorial Sloan Kettering Cancer Center, New York City, NY, USAView further author information
,
Joseph Connorsl BC Cancer Centre for Lymphoid Cancer, Vancouver, CanadaView further author information
,
Andres Forero-Torresm Seattle Genetics, Bothell, WA, USAView further author information
,
Keenan Fentonm Seattle Genetics, Bothell, WA, USAView further author information
,
Ashish Gautamn Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
,
Indra Purevjaln Millennium Pharmaceuticals, Cambridge, MA, USAView further author information
,
Rachael Liun Millennium Pharmaceuticals, Cambridge, MA, USAORCID Iconhttps://orcid.org/0000-0001-6033-4510View further author information
ORCID Icon &
Andrea Gallaminio Research and Clinical Innovation, Antoine-Lacassagne Cancer Center, Nice, FranceView further author information
 show all
Pages 2931-2938 | Received 06 Mar 2020, Accepted 29 Jun 2020, Published online: 25 Aug 2020

References

  • Connors JM. Advanced-stage Hodgkin lymphoma: new approaches based on novel therapeutic agents or treatment intensification. Cancer J. 2018;24(5):230–236.
  • Case DC Jr., Desch CE, Kalman LA, et al. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma. 2007;7(5):354–360.
  • Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer. 2013;21(3):841–846.
  • Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586.
  • Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356.
  • Evens AM, Cilley J, Ortiz T, et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137(6):545–552.
  • Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1993;11(11):2258–2272.
  • van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin’s disease. J Clin Oncol. 1989;7(12):1776–1782.
  • Landgren O, Algernon C, Axdorph U, et al. Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica. 2003;88(4):438–444.
  • Nademanee A, Sureda A, Stiff P, et al. Safety analysis of brentuximab vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant. 2018;24(11):2354–2359.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.